Search
Piperonyl butoxide
go.drugbank.com/drugs/DB09350ApprovedVet approvedIt has no pesticidal activity of its own, but acts to increase the activity of pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone. … Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. It is used for the treatment of head, pubic (crab), and body lice. Piperonyl butoxide is a synergist.
Ioxitalamic acid
go.drugbank.com/drugs/DB13444ApprovedWithdrawn[A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995.
Turpentine
go.drugbank.com/drugs/DB11120ApprovedIt is used as a solvent and base material in organic synthesis reactions. … Turpentine, also known as spirit of turpentine, oil of turpentine, and wood turpentine, is a liquid extracted from live trees, mainly pine, through distillation of resin.
Minaprine
go.drugbank.com/drugs/DB00805ApprovedMinaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair.
Dichlorobenzyl alcohol
go.drugbank.com/drugs/DB13269Approved[A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical.
Reboxetine
go.drugbank.com/drugs/DB00234ApprovedInvestigationalWithdrawnReboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.
Piracetam
go.drugbank.com/drugs/DB09210ApprovedWithdrawnPiracetam has neuroprotective and anticonvulsant properties and is reported to improve neural plasticity [A31532]. … Originally marketed by UCB Pharma in 1971, piracetam was the first nootropic drug to modulate cognitive function without causing sedation or stimulation [A31532].
Tivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigational[L32529] Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies … It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]
Moroctocog alfa
go.drugbank.com/drugs/DB13999ApprovedUse of recombinant DNA-derived clotting factor treatments, such as Moroctocog alfa, has reduced this risk. … Bleeding can range in severity from minor concerns, such as nosebleeds, to more serious events such as hemorrhaging in the joints, brain, or digestive tract [A32280].
Trofinetide
go.drugbank.com/drugs/DB06045Approved[A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union. … , making trofinetide the first and only treatment approved for Rett syndrome in the European Union.